Q3 2021 Zoetis Inc Earnings Call
Yes.
[music].
Yes.
Thanks.
[music].
Yes.
Okay.
Okay.
[music].
Okay.
[music].
Okay.
Yes.
Yeah.
Please standby your program is about to begin.
Welcome to the third quarter 2021 financial results conference call and webcast Where's the awareness.
Hosting the call today is Steve Frank.
<unk> President Kevin Investor Relations for is the latest.
The presentation materials and additional financial tables are Kurt.
We posted on the Investor Relations section of <unk> Dot com.
Presentation slides can be managed by you the viewer and will not be forwarded automatically.
In addition, a replay of this call will be available approximately two hours. After the conclusion of this call via dial in or on the Investor Relations section.
Scott Com.
At this time, all participants have been placed in a listen only mode and the floor will be opened for your questions. Following the presentation.
If you would like to ask a question at that time. Please press star one on your Touchtone phone.
If at any point. Your question has been answered you may remove yourself from the queue by pressing the pound key.
In the interest of time, we ask that you limit yourself to one question. Thank you up again with any follow ups.
Your line will be muted when you complete your question.
When posing your question. Please pickup your handset to allow optimal sound quality.
Lastly, if you should require operator assistance, please press star zero.
It is now my pleasure to turn the floor over to Steve Frank Steve You may begin.
Thank you operator, good morning, everyone and welcome to the <unk> third quarter 2021 earnings call I'm joined today by Kristin Peck, our Chief Executive Officer, and Whitney Joseph Our Chief Financial Officer.
Before we begin I'll remind you that the slides presented on this call are available on the Investor Relations section of our website.
Remarks today will include forward looking statements and that actual results could differ materially from those projections.
For a list and description of certain factors that could cause results to differ I refer you to the forward looking statement in today's press release, and our SEC filings, including but not limited to our annual report on Form 10-K, and our reports on Form 10-Q.
Our remarks today will also include references to certain financial measures, which were not prepared in accordance with generally accepted accepted accounting principles or U S. GAAP a reconciliation of these non-GAAP financial measures to the most directly comparable U S. GAAP measures is included in the financial tables that accompany our earnings press release and in the company's 8-K.
Filing dated today Thursday November 4th 2021.
We also cite operational results, which exclude the impact of foreign exchange.
With that I will turn the call over to Kristin.
Thank you, Steve and welcome everyone to our third quarter earnings call. We delivered strong results again this quarter with 10% operational growth in both revenue and adjusted net income driven by our innovative portfolio of pet care products, it aside and dermatology product.
Our U S business grew revenue, 7% operationally, while international grew revenue, 14% operationally.
In terms of speed, our companion animal portfolio generated 19% operational revenue growth in the quarter with great performance in markets around the world.
Our latest innovation in parasiticide, the triple combinations <unk> is increasing its global adoption, our groundbreaking dermatology product Apple coincided point continue to redefine and expand the category and we completed the first full quarter of sales for both of our new monoclonal antibody therapies for <unk>.
Our greatest pain in dogs, and cats Labella Sos yet.
These new products are exceeding expectations, and receiving very positive feedback from veterinarians and pet owners and European market, where they have been launched.
When you add all of this to our growth in diagnostics for companion animals, ICR business continuing to capitalize on the positive demographics for Pat.
Increased spending on pet Wilmington treatment will be sustainable well beyond the pandemic and our portfolio and pipeline have us well positioned to continue leading and innovating in this market.
Lifestyle product sales continue to present, a more complex picture for the industry and the letter with market dynamics vary widely by species and geographies.
As we expected our livestock portfolio declined 2% operationally in the third quarter, largely due to generic competition across cattle poultry and swine and most significantly in the U S. We have taken proactive strategies to protect these product lines, including the introduction of a lifecycle innovation like Jackson.
But pricing pressure remains due to the increasing effect of generic competition.
On the positive side, we saw 7% operational growth for livestock in international as markets like Brazil, Chile, and other emerging markets performed well.
Our long term advantage in livestock continues to be our diverse portfolio and strength across geographies and product categories like medicines vaccines and medicated feed additives.
We also continue to invest in R&D programs that align with our customers' long term needs for more efficient and sustainable production method, which can be built a new therapy analytics and digital solutions.
We remain on track for a record setting year with updated guidance for operational revenue growth in the range of 14% to 14, 5% and adjusted net income growth in the range of 16, 5% to 18% for 2021.
Our major catalyst for growth have performed well this year and have more runway ahead for 2022 and beyond and we'll do we make the right investments and continue successfully executing our growth strategies.
Our strength in pet care as an incredibly strong foundation across parasiticide dermatology and vaccines.
For the first nine months of 2021 are contained in our portfolio has grown 29% operationally.
We also remain very excited about the long term blockbuster potential of our new monoclonal antibody franchises in pain labella insulins, yet as they grow in Europe, and we made progress on approvals in the U S.
We currently expect approval of <unk> in the U S. In the first half of 2022 with <unk> remaining more likely in the second half.
Our revenue growth in international markets has been 20% operationally through the first nine months driven by China, Brazil, and other emerging markets. We continue to expect growth to come across both our companion animal and livestock portfolios in these markets.
Finally, our diagnostics portfolio remains a key catalyst for growth with 28% operational growth through the first nine months, we are gaining significant traction with our expansion of the point of care portfolio in markets outside the U S. We always believed international expansion with one of the biggest value driver to the Abaxis acquisition once we can.
Fine that portfolio with the globals, the wettest footprint the acceleration of international growth for diagnostics as a very positive sign and continues gaining momentum.
We also recently added digital cytology testing to our vet scan images platform in the U S U K, Canada, Australia, and New Zealand. This means we can now offer a network of expert remote pathologists. In addition to artificial intelligence technology for fecal testing.
We're seeing our strongest early adoption of <unk> images, and Germany, Australia, Spain, and the U K and we will continue developing additional applications for the platform over time.
In addition to our ongoing investments in R&D program and direct to consumer campaign, we are investing in manufacturing capacity to meet increasing demands for our new parasiticide products in monoclonal antibody therapies expansions are underway at our face a calendar of the Michigan, Lincoln, Nebraska, and Palomar Ireland.
All of these are significant multi year project to ensure we have ongoing reliable supply while maintaining a diverse global network of third party contract manufacturers that give us the greatest flexibility and redundancy.
Our supply chain team has done an excellent job over the last two years to optimize inventory levels of key products, while minimizing the impact of a challenging global supply landscape, we continue to carefully monitor and manage our supply chain and inventory.
And finally before I hand things off to Whitney I wanted to note. Our recent news about changes in our R&D leadership team longtime R&D leader, Cathy Knupp, who will be retiring at the end of the year and ensuring a smooth transition through February I am very grateful to Kathy for building, the most innovative and productive R&D organization and the animals.
Our industry and for leaving us with a rich pipeline of future innovations and R&D talent, which includes her successor, Rob Hope there Robin It was the wettest since 2015 working on many of the innovations that have come to market recently, and parasiticide and monoclonal antibodies.
He has experience running our global therapeutics, and biologics R&D organization and he's the right leader for the future of innovation at <unk>, Inc.
In closing I want to thank our colleagues for delivering another great quarter, and bringing the value of the audits to our customers. Every day, we are confident in the updated guidance, we provided and see the fundamental growth drivers of our business continuing into 2022 and beyond now let me hand things over to Wei.
Thank you Kristen and good morning, everyone.
The focus of my comments today will be on our third quarter financial results. The contributing factors that drove our performance and an update of our improved full year 2021 guidance.
In the third quarter regenerative revenue of $2 billion.
Growing 11% on a reported basis and 10% operationally.
Adjusted net income of $597 million was an increase of 14% on a reported basis and 10% operationally.
Operational revenues grew 10% with 2% from price and 8% from volume.
So on growth is comprised of 5% from new products, including Transamerica trio and 3% from our inline portfolio, primarily our key dermatology franchise.
Now, let's dive further into the details of the quarter.
Companion animal products again led the way in terms of species growth growing 19% operationally with livestock declining 2% operationally in the quarter.
Our parasiticide portfolio made the largest contribution to the companion animal growth driven by sales of <unk> trio and continued strength across our broader portfolio, including the pro heart franchise, So verica and revolution stronghold plus.
We also saw robust growth in our key dermatology products <unk> and final point.
<unk> had another exceptional quarter posting revenue of $122 million, representing operational growth of 140% versus the comparable 2020 period with year to date sales of $350 million.
We believe the global fleet tick and heartworm market will continue to expand and that our broad and innovative portfolio, which grew 32% operationally in the quarter has us well positioned to capture share and outpace our competitors.
Global sales of our key dermatology products were $321 million in the quarter growing 26% operationally.
Total sales exceeded $300 million for the first time in company history, and we remain ahead of schedule to surpass $1 billion.
<unk> sales for the year.
Our diagnostics portfolio had cut operational sales growth of 7% in Q3 against the very challenging comparative period as the third quarter of 2020 had a sharp increase in wellness visits following widescale clinic closures in the second quarter.
Our international diagnostics portfolio performed very well, which as Christine mentioned was a key component for the strategic rationale of the Abaxis acquisition.
Divestments remains the key growth driver for <unk>, and we will continue to make significant investments in new technology expand our reference lab footprint as well as provide flexible solutions to our customers.
Our equine products delivered strong results with operational sales growth of 20% in the quarter as horse shows and racing returned to pre pandemic levels fueled growth in vaccines as well as additional campaign products.
The expected decline in livestock in the quarter was primarily driven by our U S. Cuddle on U S poultry businesses as our international segment delivered operational growth across all species.
Globally, our cattle business declined 5% operationally in the quarter driven by the impact of generic competition for Jackson, and a difficult comparative quarter, resulting from COVID-19 dynamics and an earlier fall cattle run in the U S. In the third quarter of 2020.
Poultry also declined in the quarter as producers in the U S rotated through lower cost alternatives to our premium products as a result of current market dynamics.
Sales were also negatively impacted by generic competition, because the Olympics and BMD alternatives to antibiotics in medicated feed additives.
The decline in cattle and poultry offset the growth in fish.
Swan was essentially flat in the quarter as declining in the U S primarily from pricing pressure on our anti infective and vaccine portfolio. As a result of generic competition also the growth internationally and further key account expansion.
Overall, we delivered another strong quarter benchmarked against a very difficult prior year comparative period on both the companion animal and livestock sides of our business.
Now, let's discuss the revenue growth by segment for the quarter.
U S quarterly revenue exceeded $1 billion for the second consecutive quarter with revenue growth of 7% sales.
Sales of companion animal products grew 17% and thus dichotic sales declined by 13%.
For companion animal health care trends continued to be robust for excellent revenue and patient visits grew again this quarter against growth rates from the third quarter of last year, which were well above historical levels.
Our view remains unchanged that certain trends will moderate but will remain above pre pandemic levels.
Growth in U S companion animal was led by our parasiticide portfolio in our key dermatology products.
The broker trio continues to perform well with U S sales of $110 million and year to date sales north of $300 million.
This quarter is also an excellent representation of our commitment to invest in the border parasiticide portfolio as we launched a targeted DTC campaign for cohort and prevalent heartworm geographies.
Key dermatology sales were $217 million in the U S for the quarter growing 20% with significant growth for Apple Insider point.
Yes.
U S diagnostic sales grew 2% in the quarter, which as I mentioned earlier had a very difficult comparative period. However year to date performance has been strong at 23% growth.
<unk> sales declined 13% in the quarter.
Our U S coal business faced a comparative period Thats, a robust growth of third quarter performance of 2020 benefited from the early fall cattle run in terms of demand work its way through the system. In addition, generic competition has not entered the market in the third quarter of 2020.
Our generic defense strategy has been successful as we have been able to maintain a greater volume share of the solithromycin market than originally expected, although additional generics will likely enter the market in the coming quarters.
From an end market perspective producer profitability remains challenged by input costs, primarily feed and labor.
U S poultry sales decline in the quarter, a smaller fox resulted in lower disease pressure, allowing producers to expand usage of lower cost alternatives to a highly efficacious premium products.
In addition, generic competition is creating pricing pressure on our Assortments Nbn franchise.
Franchises.
Yes.
To summarize our U S operations delivered another strong quarter, driven by our innovative and robust companion animal products, along with pet care end markets displaying very strong fundamentals.
The near term weakness in our <unk> business has been expected and has been more than offset by the strength in companion animal, which demonstrates the importance of diversification across species.
Now turning to our international segment.
Revenue for our international segment grew 14% operationally in the quarter with companion animal revenue growing 24% unless tag revenue growing 7% operationally.
In the second half of 2020, we saw a material uptick in medicalization rates and standard of care by pet owners, a trend, which has continued through the third quarter of this year we.
We in turn made significant investments in advertising and promotion to capitalize on favorable market conditions and drive growth.
I don't want achieved broad based growth internationally in the quarter led by strong performance of our key dermatology products.
For the three quarters of 2021 year to date sales are in excess of total sales for the entire prior year and.
In addition, we are in the early stages of a DTC campaign for key dermatology, which we expect will create additional demand for our products.
<unk> had a strong quarter internationally led by significant growth in this empirical franchise, which benefited from DTC campaigns and drove growth in Brazil, Eastern Europe, and Latin America.
Labella amongst monoclonal antibody for alleviation of OA pain in dogs has done extremely well generating $50 million in quarterly sales and a select number of markets feedback.
Feedback from veterinarians and pet owners on the quality of life improvement for the patients has been extremely encouraging.
Our feline monoclonal antibody for alleviation of where ethane Cynthia the positive feedback from the early experience programs in Q2 and launched in the EU This quarter.
Or a payment cost is a significant unmet need in animal health and our view is that <unk> will become a blockbuster products with the pain market forecast, becoming approximately a $200 million global category overtime.
Our international diagnostics portfolio grew 20% operationally in the quarter with significant growth in consumable and instrument revenue and strong growth across a number of geographies such as the U K, Australia, China and various other markets.
Moving onto livestock, our international business again delivered growth across all species led by strong operational growth in cattle and fish.
Total growth in the quarter was driven by further key account penetration and favorable export market conditions in Brazil, and several number other emerging markets.
Our first portfolio continues to perform very well growing 21% operational.
Growth in our fish portfolio was primarily the result of increased sales of our alpha flux utilized treatment products as well as strong growth in vaccines.
Performance in swine and poultry will also fueled by growth in key accounts as well as overall market growth primarily in emerging markets.
At a market level view for international segment, all major markets grew operational in the third quarter with the exception of France, which was essentially flat in Q3.
Emerging markets was again, a key contributor to our international performance led by Brazil, which grew 2% on an operational basis.
As we expected growth in China slowed in the third quarter as lower pork prices challenged producer profitability.
However, the companion animal business in China, which grew double digits once again offset the weakness in Swan.
Overall total emerging markets has grown significantly in both the quarter and on a year to date basis.
Our international segment again delivered strong results with robust growth in companion animal and growth across all species in livestock.
On a year to date basis, our international segment has grown 20% operationally with our companion animal and livestock business businesses, each growing double digits.
While falling pork prices in China are creating a headwind that is moderating growth in swine. It is more than offset by the growth across other species and markets further demonstrating the importance of our diversity across species angiography.
Now moving onto the rest of the P&L.
Adjusted gross margin of 77% increased 110 basis points on a reported basis compared to the prior year as favorable product mix foreign exchange lower inventory charges and price were partially offset by higher manufacturing costs freight and distribution costs.
Adjusted operating expenses increased 19% operationally with SG&A expenses growing 20% operationally, resulting from increased compensation related costs.
As well as increased advertising and promotion expense and timing.
R&D expenses were 17% operationally driven by higher project spend.
The adjusted effective tax rate for the quarter was 16, 7% a decrease of 330 basis points due to favorable changes to the jurisdictional mix of earnings including increased variability related to foreign derived intangible income and an increase in favorable discrete items compared to the prior year's comparable quarter.
Adjusted net income and adjusted diluted EPS grew 10% operationally for the quarter, primarily driven by revenue growth gross margin expansion and a lower effective tax rate.
Our liquidity position remains very healthy and in the third quarter was $3 $3 billion in cash and cash equivalents following a $600 million repayment of long term debt in August.
Our financial flexibility and a very strong position, which allows us to make meaningful investments in our business, while returning excess cash to shareholders as demonstrated by our repurchase of shares or approximately $200 million in the quarter.
Now moving on to our updated guidance for 2021, we are raising and narrowing as a result of our performance in the third quarter and confidence in our ability to deliver sustained.
Sustainable future growth.
Please note that our guidance reflects foreign exchange rates as of mid October.
For revenue, we are raising and narrowing our guidance range. We projected revenue now between 777 75 billion.
And operational revenue growth between 14% and 14, 5% for the full year versus the 12, 5% to 13, 5% and our August guidance.
Adjusted SG&A expense for the year are expected to be between $1 91, and $1 94 billion.
Versus $1 87, and $1 $91 billion in our prior guidance.
The guidance range largely represents additional competition related costs as well as increased advertising and promotion spend to support growth of new products and key franchises.
Adjusted net income is now expected to be in the range of $2 two and two to two 5 billion.
Representing operational growth of 16, 5% to 18% compared to our prior guidance of 13% to 15%.
Adjusted diluted EPS is now expected to be in the range of $4 62.
So 4060 <unk> and.
Our reported diluted EPS to be in the range of $4 three.
So for those in 2009.
Now to summarize before we move to Q&A.
Three quarters, we've delivered strong operational top and bottom line growth with revenue growing 17% operationally and again raised and narrowed our full year 2020 one guidance.
We have achieved significant growth across our key franchises and are extremely excited about our new product launches and product pipeline.
Now I'll hand things over to our operator to open the line for your questions.
Operator.
And at this time, if you'd like to ask a question. Please press star one on your Touchtone phone if at any point. Your question has been answered you could remove yourself from the queue by pressing the pound key.
Again on the interest of time, we ask that you limit yourself to one question and re queue again with any follow ups. Your line will be muted when you complete your question.
Today's first question comes from Michael <unk> with Bank of America. Please go ahead. Your line is open.
Great. Thanks for taking the question guys and congrats on a strong quarter.
<unk> raised the guide I want to start on track. Some real quick you touched on generic impact in U S. Livestock, a number of times in your remarks, we assume thats predominantly from traction can you give us an update if youre seeing any stabilization there or are you expecting for the headwinds of <unk> 22, <unk> or 2022.
Or do you think I was trying to improve and stabilize from here.
Yes. Thank you we were very pleased to deliver another strong quarter.
And.
And in position to raise our guidance once again for the year with respect to Jackson as expected we continue to see.
<unk> of the low.
Jackson was down about $15 million in the quarter now our defense strategy here is working well and we are largely maintaining our market share. Although that does have the effect on on price. So we're very pleased with how the product is performing as well as accident AP.
In terms of in terms of maintaining largely the market share from a volume perspective here as you look forward we are expecting further.
So there are generic competitors to come into this space from Jackson.
Perspective, and that we believe will continue into the into next year as well.
And the only thing I would add there is as we said this is completely in line with our expectations not just that we gave this year, but that we've been talking about with the generic enters we generally said it takes somewhere between 20% to 40% over a number of years. We said at the beginning of this year that that would likely be a little factor and we are on track to be doing that.
We expect it to probably somewhere around that 20% head on price for us on this product in the year. So in line with the expectations Mike.
Thank you we'll take our next question from Louise Chen with Cantor. Please go ahead.
Hi, Thanks for taking my question here. So as we start to think about 2022, what are some of the pushes and pulls here for example will recovery from food services and restaurants be a tailwind in 2022 for livestock and what else should we be thinking about thank you.
Thanks Luis.
And as a.
A real headwind for us.
But overall, we really think that durable broke drivers you saw this year really continue into next year and we're pretty confident about that.
Yeah.
We'll take our next question from Nathan Rich with Goldman Sachs. Please go ahead.
Thanks, so much if I could maybe follow up on the revenue outlook what need for four Q I think historically <unk> has been a bit of a stronger quarter. You mentioned the competition on drugs and is there any other dynamic that we should have in mind in terms of the revenue kittens.
For the fourth quarter, and I guess, what the focus on inflation and cost pressures in the market.
Did you feel like you've seen any pre buying a products or stocking up from customers in either the livestock or companion business. Thank you.
Yeah sure look on we can see this is really sore underlying market dynamics overall.
Al portfolio is really well positioned echoed case before very well against against those dynamics as we discussed on the prior critics call. What we're seeing it comes a growth rate in the second half of this year, it's more a reflection of how the phasing occurred last year versus this year given our position in the market again Stowmarket day, So we can interface.
Face here, if you look at last year, the second half had almost 17% more revenue in the past in the first half of last year and so that's really what's driving the copier does the phasing of last year, where this year is a little bit more normalized as Christian just just referenced we see a number of growth drivers for us not only from the overall.
Market, but also a portfolio across Paris term.
When you look at pain diagnostics as well.
One area the areas that were watching including Jackson to your point around inflation is.
Given a portfolio of innovative products that we have in the mandatory for those products the position as well to take price and you saw 2% price.
And a quarter.
10% operational growth and will continue to look at the opportunities to continue to do that as we go into next year you saw in the quarter gross margin is actually expanded to 110 basis points versus.
Two three and so and that despite some some headwinds in the areas of freaks et cetera. So we'll continue to monitor those and take price, where we can get into innovative products that we went to the market will assessments.
And our next question is from John Block with Stifel. Please go ahead.
Great. Thanks, guys. The morning, Keybanc instead of a couple of the person on livestock and quite honestly was plug.
Pleasantly surprised by the international livestock up 7% operational there's just a lot of noise out there with other companies and swine chatter. So I guess the first question is.
Was that a queen number.
Pull forward and maybe just talk to this market overall do you still view it as a low single digit grower.
For you this year with eventual improvement in mid single digits and call. It 22 Slash 23.
And then just attended.
Christian or my knee I know, we're not going to get a 22 guy, but maybe conceptually at a high level. How do we think of 22 in terms of Ah.
A year, where the Delta how do we think that the delta between revenue and EPS growth and I guess, where I'm going with this is a lot of innovation for you where you are still dominating the market. So conceptually do we just think about it as another year of spending supporting the portfolio of D. T C where the delta between those two revenues, whereas an EP.
Might be a little bit tighter than prior years and sorry for the long winded questions. Thanks.
Sure.
I'll take the first part of the question and I will let let me take a second half dot.
Livestock is a complex picture.
I think it's quite well founded in the sense of not just the difference between you as an international but the difference between the species. So as you rightly mentioned the.
The U S is down significantly in life.
Pretty much generic competition against your accent Hello next to some other products that we mentioned before but to your point international was upsetting.
It was filled with a really rough time in China as you saw in the quarter with China livestock down about 10% more than made up for by China's companion animal and really it has to do with the mix between species that are growing quite quickly like fish.
Cattle and poultry may be struggling, but you look at strong growth in emerging markets, which is quite really booing livestock.
Set in previous quarter.
How are you at life Dot Gov does not mean, how overall lifestyle. So I think we really the diversity of our portfolio across species across geographies continues to really be one at that strength for us at least and.
And we do think overall, you'll see a flat for low single digit.
Wroth overall across accompanying for us and livestock that may be a little bit slower than the market as we said because.
Track than some of the key that we have and ultimately once we lost some of those at all we think you do go back 23 24 and the.
Two a mid single digits exactly what we've always been so the historic growth of livestock is around 4% and as we said we think it actually returns there and what's the reason to believe well if we're growing international in the quarter at 7% and really the U S is mostly getting hit by the generic once we laughed as we do believe you can get back to our livestock road and the sort of mystical.
That's the way to start we happen, but I'll, let let me take your second question yes.
Just just before here.
We are well positioned.
Going out of this year.
Here.
To continue to sustain growth beyond beyond this year in terms of how you might see things flow through the P&L are long term value proposition is to grow adjusted net income faster then revenue.
We don't see any reason to depart from that however, given the opposition across the number of really keep brand of demand that we see will take the opportunity to invest behind those brands.
Drive VTC another awareness campaigns et cetera, we also are investing in.
R&D as well as the diagnostics in other areas that we believe will help us accelerate.
Hence growth going forward, so that may at times cause that that difference to be able to tighter as you said from time to time, but if you drive that growth that enhance level of growth that we see if given the opportunity that we see in the market.
Thank you we will take our next question from Aaron right with Morgan Stanley. Please go ahead.
Hey, Thanks can you provide us I mean that checked on the contributions from like breland to Lindsey and a quarter or any metrics around reorder reads the products in certain markets and how the launches progressing relative to your expectations at this point in the expected timeline again for the U S lunch and then.
Second just more broadly uncontaminated more trends any monthly metrics. He can give us over the course of the quarter and kind of what's expected for the fourth quarter and beyond in terms of in terms of the underlying demand tend to cross that market.
We continue to be very pleased with the performance of.
In Philadelphia in the European markets, where we launched the product the feedback has been very very strong from.
And the owners as well.
We saw a $50 million of revenue from the gorilla in the quarter and about $2 million from Celeste.
Again.
Four quarter of those products being in those.
Select markets for us.
It turns though where we're expecting approval for next year, we continue to expect approval for labella.
As I mentioned in the first half of the year and what date was that I'm sorry.
So.
So.
So then to in the first half with umbrella more likely.
Half of the year in the U S.
I'll take the second half of your question Aaron with regards to U S companion animals.
We don't have the monthly data, but just putting some of it in context, we believe that we look at the data overall right now we're seeing overall that clinic revenue growing 7%, which is higher than any historical right. It's been a little bumpy over the year I mean, the weather and lots of different dynamics have been driving it.
You saw 8% in Q1, 14% in queue to we're seeing 7%.
The way, we should've heeded as we think it overall will be higher than historical norms. I mean is it is the double digit thing you saw consistently in 2028, no, but I don't think we thought very weak and you talk to you. One is a huge bounce back in the second half as we saw last year, we do think that.
Revenue at that clinic, we will continue to grow above historical rates.
We're not really sure as I said last quarter that we think that's going to be double digit, but historically grew five perfect.
Going to be seven to eight I think argue as it will still be stronger than normal, but maybe not in the double digits.
Overall, but I mean still seeing strength you any one of you who have been trying to get an appointment for your dog or your cat does that it's pretty challenging to get one so mostly because of the demand really does remain high there.
And our next question comes from Chris start with J P. Morgan. Please go ahead.
Alright, great. Thanks, so much for the questions.
This is my first one.
<unk> portfolio, you feel a 1 billion dollar franchise here, but it's really about competition coming in 2022 or beyond.
What are you anticipating in terms of the impact that a competitor launched could have I think historically, you've talked about a second entry.
More building the market then maybe directly cannibalizing your existing business, but it says you've had a longer window of time to develop this like do reach a point where.
Live launch I guess more impact your growth versus.
Part of the question is how much more room is there for market expansion as a new player comes in thanks, So much.
That's correct yeah.
Or a portfolio has continued to grow and I think what we really discovered it there's still a large number of untreated animals out there.
So if you look at we simply they are 7 million dogs that are diagnosed.
With some form of Itchiness, they're still not being treated so.
So we do believe they are significant market growth are still geographic expansion.
Really invested heavily in direct to consumer advertising to grow this market people are home more with our pets, they're spending more time. So I think people are really starting to notice this edge and bothering them more maybe than it did historically so they are seeking help we've also really invested in programs such as our <unk>, our pet care rewards programs.
Which is making customers loyal to our product. So we have been expecting competition to be Frank we probably thought it would happen before now, but we think there's lots of room to continue to grow this market and so will it remain at 26%. If you saw the quarter our growth might go down a little bit, but I still think this will be a growing market for us just given the large number of untrue.
A dog.
You have been around the globe.
No next question comes from but largely per song with Barclays. Please go ahead.
Good morning, and thanks for the questions.
Painful.
China.
Paul a side of blind and the person you often spoken about China is a major market understandably Kenny.
Can you help us understand the expectation that on the market.
Any compiling range of prizes anything this market some board and also farm behind wood applicant B in terms of getting interviews are launched in China. Thank you.
Yeah, I'll I'll start and see with Kristen what's to adhere with the sorts of China is expected we saw growth facility in China this quarter with about 1% growth in the quarter, but keep in mind, China has actually going 35% on a year to be basis.
It gets very solid compared to last year, where.
Where we saw 63% growth in the quarter and swine was actually 159% quarter last year, the pricing dynamics for pork, which we discussed on the last call started about mid June so we expect it to see.
So the decline in the pork area now the other part of your question as long term what are we expecting in the market. We do see continued opportunity.
To grow substantially in China over time, as we bring more and more of our products to the market, but also if you look at what's happened since.
African swine fever, you see a concentration more and larger Purdue.
Producers versus backyard forms, we think that will bode well in terms, though for medical physician overtime as well and for our premium products with respect to swine and then all of a companion animal side, we continue should really robust growth.
I'm preparing animal we saw double digit growth this quarter and comparing animal, which obviously was partly offset by by the by swine. So long term, we can take to expect really solid growth.
In China, which is our second largest market.
Driven by the market dynamics that we discussed although there may be cycles that will see of swine as weird as we're going through right now some questions that way.
Only thing that I can add to that.
We obviously have launched Apple call there.
It is doing well it is.
Growing because of specialty products marketed traditionally been.
Mostly a primary care general this market. So we are really excited to grow that and I think we have a very strong pipeline of products coming into China, new innovation that we're going to be bringing in just like we brought an apple quality approval right outside of point, which has not yet launched there and honestly lots of products behind that thought that when we're really excited to be launching in China.
It is our second largest market. We do think it is going to continue to have very strong growth.
Whitney said with our year to date at 35% were really bullish on our ability to continue to grow in China.
The next question comes from Steve Scholar with Cohen. Please go ahead.
Thank you I have a question on labourer Insulins here in Europe. There are several parts of the question or owners are returning monthly for the next injection or is the time between injections longer than that what does the average patient cost of each injection and just to clarify. Thank you said collinsia and cats is a two.
100 million dollar opportunity why is that why is that only 200 million why isn't it multiples of that thank you.
Sure I can start there we are really pleased with umbrella. Yes. We are seeing animals are charged I don't have a specific number of days.
That they're coming back we can certainly look into that and see if we can get that data for you. It is priced at a premium to both rendell as well as to gallop brands on the market.
Given it has a phenomenal about safety and efficacy profile. It has been priced at a premium the price obviously varies from market to market. So I don't think we have overall information with regard to the second part of your answer until Wednesday.
Is it a quite different market. So although today the market a dog that's 400 and we believe we can tabulate the market is actually pretty hired to size and cat. There's very few approved product out there today to treat cat. So.
Even say what it is I mean, it's not zero, maybe tens of millions, it's certainly not hundreds of millions of dollars and capitalist medicalize. The dog. So you really have to first medicalize. Those cat you have to be able to calculate the hide their pain. So you also have to find a way that pet owners can notice pain in cat better and identify.
And bringing them to that that will do recently finished a smaller market at that number a catheter medicalize are just smaller and then the number that are actually treated as really small. So the first thing is you need to be able to identify and cast a pet owner convincing them to take their half of that and build the market from scratch me category when they used to call the vet when they're catalist Sir.
For pain.
Great. We're told there really wasn't anything there's no product in the U S. For example whatsoever. So it's really about the training pet owners that there is a product that can neither have needs and helping back really bringing the cap into the vet I mean, a lot of pet owners don't by putting their cat.
Increased to bring them to the vet as you probably know, but we're very confident that we have a strong pipeline for cat they will increasingly medicalized cash overtime and help build that market, but as we said just given the number of macolyte packed it will be a smaller market than the dog faced and it will likely take a little longer to build it.
And our next question comes from Christine range with William Blair. Please go ahead.
Hi, Congrats on like Greek courtroom good morning.
My question is that we noticed the trio declined sequentially for the first time. So I was just hoping to have some color on this and I'm kind of how it's performing versus your expectations. Thanks.
Sure.
We saw another strong quarter across our first this is my choice.
Small animal purses eyes grew about 32% in the.
In the quarter with $391 billion, we had trio sales of $122 million.
So far this year on the day to day business the qualification do extremely well, particularly in our large corporate accounts with penetration rates about 90% and we're thinking about 80% of the orderlies as well. So we continue to gain share and is very large market.
Call last year, we launched the product and so we've now with our lapping it and and in terms of versus.
Sort of seasonality starts to play into it good in terms of what you might see as well. So this is really in line with us locations and we couldn't be more pleased with how the prices on in the market and now that we've really penetrated well the large corporate accounts with not going into some of the mid size accounts as well. So we continue to see the cloud of game.
Mentum.
Again, among those traditions.
Your next question comes from Nirvana tie with city. Please go ahead.
[noise], Hi, Bemoaning, how can you change capsule pet ownership going forth an average revenue.
Kenyan animal and then he can.
How much do you think that makes sense and can I quickly ask are you able to comment on them You Commission investigation.
<unk> awesome.
Understandable Terminator two antitrust.
Litigation. Thank you.
Sure.
With your question with regard to the investigation and then when they can take the second half of your question a companion animal.
Easy inspection pertains to the west is decision to discontinue the clinical development of a single experimental drought Kennedy.
Working with the easy to ensure it has all the necessary information that it needs and we are confident that we can allow the concerns with chat prompted the investigation.
I think your second part of the question was a companion animal trends.
7%, which was broken out between 3% on traffic and 4% of 10 per visit and then like make it that a comment on that yeah. Sure is Krystal mentioned, we saw 7% revenue growth for events with about.
With visits up 3% and the revenue per visit up about 4% and desktop against acquire a year, where we saw will increase in the third quarter in terms of business et cetera, given the effects of the pandemic. We continue to expect that these statistics will continue to be above reproach demick levels.
Albeit moderate from their peak one other important to two other important points to recall here.
Is that if you look at that ownership or more were seeing.
Below meals and Jessie brings us into their homes and they are doing a lot more research looking at pet care and wellness and they're willing to spend more on their past so with the increase pet ownership. We took that to continue to provide really strong fill in the industry for.
Swimming on pets, as we look forward and those those tests continued to age as well.
The next question comes from David Steinberg Jeffries. Please go ahead.
Thanks in the morning, let a question on thanks for complications for us.
I know it's been a visit.
Alrighty then thank initially.
Even happened this year I think it is.
Been pushed to the right three times.
Laughs to the second half of 22 and just curious.
No I know competitive as tight lipped about what they're doing but any any thoughts from urine and why.
Do continues to be a delay who do you think it's regulatory or could you be technical and technical.
It could delay constitution for many years to come in and then just hypothetically.
Competition comes into terms that went around the same time as.
Competition comes for some trio.
You have the flexibility to show both segments.
During this period thanks.
Sure.
I wish we knew exactly I mean, we have the same periods that you do that there could be a certain technical reasons for self competitors and let me be fair everyone's working in the space. This is Paris suicide is the largest single market and animal health at $5 billion. Now I think if you are pretty much any of the large companies we compete with they're all trying to come up with their own triple.
[noise] combination so I don't know that's the same thing that's holding each of the companies back I mean, we're not really clear.
Well it could be regulatory it could be technical it could be manufacturing.
CMC, we're not exactly clear and to your point and it really very few public companies, who actually disclose much about the pipeline to our ability to know where people are is quite limited.
We just and I noticed a little starting to keep pushing it out.
Sort of like six to 12 months or whenever you ask that question because if we haven't seen it and we haven't heard anything corporate accounts and they're negotiating with that we've made it's definitely another three and recording with another three months out and that's really where some of our thought come from and yes. We are confident that even if you'll see like we are planning on competition and these key products.
I think that's the strength and diversity of our pipeline globally that makes us confident we can continue to grow above market. I mean, we've got diagnostics and it got pain that we still think they're going to be growing in Europe to be honest with you. It's still a lot of unmet medical needs. So yes, we remain confident that we can grow above the market and even as we can start to.
Faced competition and some of these key franchises.
It will take a follow up from below cheaper side with Barclays. Please go ahead.
Hi, Thank you for the hold up.
Just.
Question on drugs sale, I mean women to date in detail, but I know that you got approval for addressing gaping July probably launches in diamond. Thank you.
So what are the expectations from the camp, even more too and children the market state flat or is the scope for these to anyone.
Gold and thinking you're on the same and see that until now.
Uncle launched generally inclusions you call on a couple of more generates one anymore I expecting next deal. Thank you.
Sure Jackson K P was part of our defense strategy.
I don't think it's going to be.
Restart of growth for us necessarily to market as we're seeing generic competition, but it is.
Let me outline and it's.
Yup remarks in the beginning of this call. It helps us retain our share it provides incremental innovation incremental benefit to our customers in a reason obviously to stay with that yes.
Yes, we have in the U S at two competitors so far.
Heard after three more are potentially coming.
I don't know why they would have expected and this year, so they're approval whether or not they actually enter the market.
Or not really act rapture way and found that but we would say we probably have.
A few more entering.
It appears we have no further questions I'll return, the Florida, Kristen pet for closing remarks.
Great. Thank you everyone for your questions today and for your continued interest and so on it.
To summarize I think we delivered another strong quarter of results driven by our diverse global portfolio and strength and pet care parasiticide in dermatology products, we're raising our guidance for the full year 2021, and we remain on track for a record setting year for us and we are continuing to invest in the areas to support our long term growth and.
We remain confident in the fundamental growth drivers for animal health and for the lettuce into 2022 and beyond so thanks, so much for joining us today have a great day.
This will conclude today's program. Thanks for your participation you may now disconnect.
[noise].